国产精品国产精品一区精品国产自在现偷99精品国产在热2019国产拍偷精品网国产精品视频全国免费观看,国产精品v欧美精品v日韩精品青青精品视频国产久久国产精品久久精品国产亚洲精品国产精品国产欧美精品一区二区三区,国产精品第一页国产亚洲精品国产福利国产精品自拍国产精品视频在线观看亚洲国产精品一区二区久久国产精品国产三级国产专不,国产精品视频大陆精大陆国产国语精品2019精品国产品对白在线285年香蕉精品国产高清自在自线隔壁老王国产在线精品在线观看精品国产福利片,国产三级精品三级在专区精品国产自在现偷国产精品一区二区三区国产日韩精品欧美一区喷水亚洲精品国产精品国自产国产在线精品一区二区不卡

熱門搜索:A549    293T 金黃色葡萄球菌 大腸桿菌 AKK菌
購(gòu)物車 1 種商品 - 共0元
當(dāng)前位置: 首頁(yè) > ATCC代理 > CLNH5.5
最近瀏覽歷史
聯(lián)系我們
  • 0574-87157013
  • mingzhoubio@163.com
  • 浙江省寧波市鎮(zhèn)海區(qū)莊市街道興莊路9號(hào)
  • 創(chuàng)e慧谷42號(hào)樓B幢401室
CLNH5.5
CLNH5.5
規(guī)格:
貨期:
編號(hào):B164269
品牌:Mingzhoubio

標(biāo)準(zhǔn)菌株
定量菌液
DNA
RNA

規(guī)格:
凍干粉
斜面
甘油
平板


產(chǎn)品名稱 CLNH5.5
商品貨號(hào) B164269
Organism human (B cell); human (myeloma)
Tissue cervix
Cell Type hybridoma: B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2  [Cells contain Epstein-Barr virus]

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease squamous cell carcinoma
Applications
The antibody reacted with cell lines derived from carcinomas of the cervix (CaSki, HeLa), lung (T293H, Calu-1 and SK-MES-1), prostate (LnCap), vulva (A431), and melanoma (SK-MEL-28).
The antibody was negative for normal fibroblasts, T lymphocytes and peripheral blood lymphocytes.
The antibody may be useful in therapy and diagnosis, both in vitro and in vivo.
Storage Conditions liquid nitrogen vapor phase
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Derivation
Lymphocytes were isolated from a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.
B lymphocytes were fused with UC 729-6 cells (see ATCC CRL-8061).
The antibody reacted with cell lines derived from carcinomas of the cervix (CaSki, HeLa), lung (T293H, Calu-1 and SK-MES-1), prostate (LnCap), vulva (A431), and melanoma (SK-MEL-28).
Clinical Data
Lymphocytes were isolated from a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.
The antibody may be useful in therapy and diagnosis, both in vitro and in vivo.
Genes Expressed
immunoglobulin; monoclonal antibody; against human cervical carcinoma
Cellular Products
immunoglobulin; monoclonal antibody; against human cervical carcinoma
Comments
The fusion line, CRL-8061, is reported to be EBNA positive.
Lymphocytes were isolated from a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.
B lymphocytes were fused with UC 729-6 cells (see ATCC CRL-8061).
The antibody reacted with cell lines derived from carcinomas of the cervix (CaSki, HeLa), lung (T293H, Calu-1 and SK-MES-1), prostate (LnCap), vulva (A431), and melanoma (SK-MEL-28).
The antibody was negative for normal fibroblasts, T lymphocytes and peripheral blood lymphocytes.
The antibody may be useful in therapy and diagnosis, both in vitro and in vivo.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
Subculturing
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10(5) viable cells/ml. Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml.
Medium Renewal: Every 2 to 3 days
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Temperature: 37.0°C
Isotype IgM
Name of Depositor HH Handley, Regents of the University of California
Deposited As human (B cell); human (myeloma)
U.S. Patent Number
References

Handley HH, et al. Methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies. US Patent 6,051,387 dated Apr 18 2000

Handley HH, et al. Human-human hybridom for neoplasms CLNH5 and CLNH11 specific antibody compositions. US Patent 6,051,229 dated Apr 18 2000

Handley HH, et al. Human-Human CLNH5-specific antibodies. US Patent 6,090,924 dated Jul 18 2000

Glassy MC, et al. Genetically stable human hybridomas secreting tumor-reactive human monoclonal IgM. Cancer Invest. 5: 449-457, 1987. PubMed: 3501329

梅經(jīng)理 17280875617 1438578920
胡經(jīng)理 13345964880 2438244627
周經(jīng)理 17757487661 1296385441
于經(jīng)理 18067160830 2088210172
沈經(jīng)理 19548299266 2662369050
李經(jīng)理 13626845108 972239479
贺兰县| 通许县| 桂林市| 平谷区| 南京市| 彩票| 海城市| 五莲县| 赤水市| 鲜城| 东港市| 宾阳县| 田东县| 南澳县| 廊坊市| 秀山| 梧州市| 宣城市| 铜山县| 宁海县| 黄石市| 油尖旺区| 攀枝花市| 云林县| 平顶山市| 清丰县| 信阳市| 涡阳县| 梁河县| 阜平县| 四子王旗| 福海县| 彭州市| 四子王旗| 信丰县| 连城县| 峨眉山市| 清徐县| 平山县| 尖扎县| 策勒县|